Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its news flow reflects the progress of these programs. Company announcements highlight clinical data from trials of rondecabtagene autoleucel (ronde‑cel, also referred to as LYL314) in relapsed and/or refractory large B-cell lymphoma (LBCL), including reported overall response rates, complete response rates, durability of responses, and safety findings from Phase 1/2 and pivotal studies.
News updates frequently cover milestones in Lyell’s pivotal development of ronde‑cel, such as the initiation and conduct of the single‑arm PiNACLE trial in the third‑ or later‑line setting and the Phase 3 PiNACLE – H2H head‑to‑head trial in the second‑line setting against approved CD19 CAR T-cell therapies. These releases often include details on trial design, patient populations, endpoints, and presentations at major scientific meetings like the American Society of Hematology (ASH) and the International Conference on Malignant Lymphoma.
For solid tumors, Lyell’s news also reports on LYL273, a GCC‑targeted CAR T-cell product candidate in Phase 1 development for refractory metastatic colorectal cancer. Disclosures include response rates, disease control rates, safety observations, and regulatory designations such as Fast Track status from the U.S. FDA. Additional corporate news items describe licensing transactions, equity financings, and operational updates that support the advancement of Lyell’s pipeline and manufacturing capabilities.
Investors and observers following LYEL news can use this page to review company-issued press releases on clinical trial readouts, regulatory designations, scientific conference presentations, licensing agreements, and capital raises related to Lyell’s CAR T-cell programs in hematologic malignancies and solid tumors.
Lyell Immunopharma has announced that its investigational LYL797, a ROR1 CAR T-cell therapy, will be presented at the AACR 2022 Annual Meeting from April 8-13 in New Orleans. The therapy employs advanced T-cell reprogramming technologies aimed at treating solid tumors. Preclinical data will be highlighted, showcasing Gen-R and Epi-R technologies that enhance T-cell durability and functionality. The poster presentation is scheduled for April 12, featuring Spencer Park, PhD.
LYL797 has received FDA clearance for Phase 1 clinical trials.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) has appointed Gary Lee, Ph.D., as its new Chief Scientific Officer. Dr. Lee brings over a decade of experience in translational cell and gene therapy, aiming to advance the company’s research pipeline. This strategic move reflects Lyell's commitment to developing a multi-modality cell therapy pipeline using its innovative T-cell reprogramming technologies. Concurrently, Nick Restifo will transition to a scientific advisor role, continuing to support the company's programs.
Lyell Immunopharma announced the FDA has cleared an IND application to start a Phase 1 clinical trial for LYL132, a T-cell receptor therapy targeting NY-ESO-1 in patients with solid tumors. This therapy utilizes Lyell’s Epi-R technology, aimed at overcoming barriers in adoptive cell therapy by promoting T cell properties of durable stemness. The clinical trial will focus on advanced synovial sarcoma and myxoid/round cell liposarcoma. This clearance marks a significant milestone for Lyell, indicating progress in their collaboration with GSK and their commitment to cancer drug development.
Lyell Immunopharma, a T-cell reprogramming company, will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:00 PM ET. The company plans to showcase its diverse pipeline, including LYL797, a CAR T-cell therapy for solid tumors, with patient screening expected by Q1 2022 and preliminary data in 2023. Additionally, Lyell will discuss its innovative technologies, Gen-R™ and Epi-R™, enhancing T-cell functions. The newly established LyFE™ Manufacturing Center will ensure quality and efficiency in cell product production.
Lyell Immunopharma has received FDA clearance for its IND application to begin a Phase 1 clinical trial for LYL797, a novel CAR T-cell therapy targeting ROR1 in solid tumors. Expected to start screening patients by Q1 2022, LYL797 aims to tackle T-cell exhaustion and enhance durable stemness using Lyell's innovative technologies, Gen-R and Epi-R. The trial will initially focus on patients with relapsed/refractory triple-negative breast cancer (TNBC) and later include those with non-small cell lung cancer (NSCLC). Initial data is anticipated in 2023.
Lyell Immunopharma has announced the commissioning of its LyFE Manufacturing Center in Bothell, WA, complying with FDA's cGMP standards. The facility, operational since April 2021, is designed to produce cell products at scale for upcoming clinical trials, including CAR, TIL, and TCR programs. It incorporates advanced data analytics for real-time monitoring and process optimization, supported by a partnership with Amazon Web Services. This infrastructure is pivotal in Lyell's efforts to address challenges in T-cell therapy, aiming for effective treatments for solid tumors.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced that Dr. Rick Klausner has resumed his role as Chair of the Board after a temporary medical leave. CEO Liz Homans expressed gratitude for Klausner's health and his ongoing scientific guidance. Klausner emphasized the company's mission to develop curative cell therapies for solid tumors and acknowledged Cathy Friedman's leadership during his absence. The company utilizes its proprietary Gen-R and Epi-R platforms to address challenges in adoptive T cell therapy.
As of September 30, 2021, Lyell Immunopharma reported cash and investments totaling $936.4 million, bolstering its multi-modality cell therapy pipeline. The company anticipates submitting four IND applications by the end of 2022 and is actively expanding its research, development, and manufacturing capabilities.
In Q3 2021, research and development expenses rose to $31.4 million, up from $24.5 million in Q3 2020. General and administrative expenses also increased to $21.2 million from $13.6 million. The net loss widened to $48.9 million compared to $35.7 million in the prior year.
Lyell Immunopharma (LYEL) will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021, at 2:00 PM ET. The event will focus on T cell reprogramming aimed at curing solid tumors. Interested parties can access a live webcast via the investor relations section of the company's website, with a replay available for 90 days afterward. Lyell is dedicated to overcoming major barriers in adoptive T cell therapy through its innovative Gen-R and Epi-R platforms.
Lyell Immunopharma (LYEL) reported significant advancements in operational capacity and financial health for the second quarter of 2021. The company achieved operational readiness at its LyFE manufacturing facility, crucial for upcoming clinical trials. As of June 30, 2021, cash, cash equivalents, and marketable securities reached $974.8 million, bolstered by $391.8 million from its IPO. While R&D expenses declined compared to 2020, G&A expenses rose due to increased stock-based compensation. The net loss decreased to $62.6 million for the quarter, indicating improved cost management.